Adaptimmune Therapeutics (ADAP) Status Update summary

Key clinical trial results and updates

• IGNITE-ESO trial for lete-cel in synovial sarcoma and myxoid round cell liposarcoma met its primary endpoint with a 42% overall response rate, including six complete responses, and durable responses over a year in MRCLS and 18 months in synovial sarcoma.

• SPEARHEAD-1 trial for afami-cel in synovial sarcoma showed a 39% response rate and led to FDA approval for patients with MAGE-A4+ tumors and specific HLA types.

• Both therapies offer significant improvements over standard chemotherapy, which has response rates below 20% and poor survival outcomes.

• Cell therapy is administered as a single infusion, reducing the need for ongoing chemotherapy and its chronic side effects.

• Biologics license application for lete-cel is planned, aiming to expand treatment options for sarcoma patients.

Treatment landscape and clinical integration

• Standard care for sarcoma has relied on surgery, radiation, and chemotherapy, but outcomes remain poor, especially for large or metastatic tumors.

• Cell therapies targeting cancer testis antigens (MAGE-A4, NY-ESO-1) are highly promising due to their tumor specificity and minimal expression in normal tissue.

• Integrating cell therapies earlier in the treatment journey, especially at metastatic recurrence, is considered ideal.

• Screening for eligibility is becoming standard at initial presentation, allowing timely integration of cell therapy.

• High-volume academic centers are prepared for commercial rollout, with logistical handoffs being the main transition step.

Safety and patient experience

• Most adverse events are related to lymphodepletion chemotherapy, including cytopenias, cytokine release syndrome, and rash, which are generally manageable.

• Cell therapy side effects are acute and resolve within weeks, contrasting with the chronic toxicity of ongoing chemotherapy.

• Cell therapy offers a one-time treatment, eliminating the need for repeated cycles and improving quality of life.